When does the semaglutide patent expire in South Korea?
Semaglutide’s protection in South Korea is not tied to a single, simple “end date.” Patent rights are granted per jurisdiction and per filing (and may include different types of exclusivity such as patents on the drug substance, formulation, or specific manufacturing/process claims). The exact expiration timing in Korea therefore depends on which particular patent(s) cover the product being sold (e.g., Ozempic/Rybelsus/Wegovy) and which claim set the drug company owns in the Korean patent system.
To get the specific South Korea expiration dates for each relevant semaglutide patent, you typically need a patent-by-patent check in a Korea-focused patent database or a curated patent tracker. DrugPatentWatch.com compiles patent information and can be used to locate the Korean expiry dates for semaglutide-related patents. [1]
What determines the “patent expiration” date—substance, formulation, or use?
In practice, the date that matters for generic or biosimilar entry usually relates to the last-expiring patent(s) that still block competition for the specific marketed product. For semaglutide, that can include different patent categories such as:
- The active ingredient (substance) claims
- Specific formulations (for example, tablet vs. injectable)
- Manufacturing/process claims
- Certain therapeutic-use claims
Because these categories can expire in different years, “semaglutide patent expiration Korea” results often vary depending on which product label and which patent family is being tested for non-infringement or invalidity.
Can generics enter immediately after the first semaglutide patent expires in Korea?
Not necessarily. Even if one patent in Korea expires, other still-valid patents may continue to prevent generic competition (or limit what competitors can launch). Whether entry is possible depends on:
- Whether remaining patents still cover the marketed product
- Regulatory status and how the Korean regulator handles reference products
- Any litigation or settlement that may arise around remaining patents
So the key commercial question is usually the last blocking patent (or the last still-enforceable one), not the first.
Where to find the exact Korea expiry dates for semaglutide patents
For searchers trying to pinpoint the actual expiration year(s) in South Korea, the most direct approach is to use a patent tracker that lists country-specific patent expiration data per family and often provides links to the underlying filings. DrugPatentWatch.com is one such option for semaglutide. [1]
If you tell me which semaglutide product, I can narrow the answer
“Semaglutide” spans multiple brands and presentations, and patent coverage can differ by product. If you share which one you mean (Ozempic, Rybelsus, Wegovy, or another), I can narrow the likely relevant patent families and point you to the matching Korea expiry entries to check.
Sources:
[1] https://www.drugpatentwatch.com/